株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

細菌性結膜炎:パイプライン分析

Bacterial Conjunctivitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 227541
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
細菌性結膜炎:パイプライン分析 Bacterial Conjunctivitis - Pipeline Review, H2 2016
出版日: 2016年09月30日 ページ情報: 英文 42 Pages
概要

結膜炎とは、結膜(眼球の白い部分を覆う膜)が赤い炎症状態となることを指します。「はやり目」(pink-eye)という言い方が流行性(細菌性)結膜炎を指す言葉として一般的に使われていますが、他にもアレルギー反応や、大気汚染・喫煙・有害煙霧のような化学的刺激によっても生じます。流行性結膜炎は児童によく見られ、感染力が非常に強い状態にあります。

当レポートでは、世界各国での細菌性結膜炎治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

細菌性結膜炎の概要

治療薬の開発

  • 細菌性結膜炎向けパイプライン製品:概要

各企業で開発中の細菌性結膜炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

細菌性結膜炎治療薬:開発中の製品の一覧(企業別)

細菌性結膜炎治療薬の開発に従事している企業

  • Cellceutix Corporation
  • 第一三共
  • InSite Vision Incorporated
  • NovaBay Pharmaceuticals, Inc.
  • Ocular Therapeutix, Inc.
  • 千寿製薬
  • Shire Plc

細菌性結膜炎:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • auriclosene
  • azithromycin
  • azithromycin
  • brilacidin tetrahydrochloride
  • ISV-405
  • levofloxacin
  • モキシフロキサシン塩酸塩 SR
  • SHP-640
  • 塩酸バンコマイシン

細菌性結膜炎治療薬:最新の薬剤プロファイル

細菌性結膜炎治療薬:開発が休止状態の製品

細菌性結膜炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8514IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2016, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape.

Bacterial conjunctivitis is an inflammation of the conjunctiva caused by pathogenic bacteria. Bacterial conjunctivitis is usually caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus sp, or, less commonly, Chlamydia trachomatis. Symptoms include redness in the white of the eye or inner eyelid, itchy eyes, blurred vision, increased sensitivity to light and burning eyes. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 2 and 1 respectively for Bacterial Conjunctivitis.

Bacterial Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacterial Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacterial Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacterial Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacterial Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bacterial Conjunctivitis Overview
  • Therapeutics Development
    • Pipeline Products for Bacterial Conjunctivitis - Overview
  • Bacterial Conjunctivitis - Therapeutics under Development by Companies
  • Bacterial Conjunctivitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Bacterial Conjunctivitis - Products under Development by Companies
  • Bacterial Conjunctivitis - Companies Involved in Therapeutics Development
    • InSite Vision Incorporated
    • NovaBay Pharmaceuticals, Inc.
    • Shire Plc
  • Bacterial Conjunctivitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • auriclosene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • azithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISV-405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHP-640 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vancomycin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bacterial Conjunctivitis - Dormant Projects
  • Bacterial Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 17, 2015: Manhattan U.S. Attorney Settles Civil Fraud Claims Against Inspire Pharmaceuticals For Its Misleading Marketing Designed To Cause Prescriptions Of Azasite For Non-Fda Approved Uses
      • Mar 17, 2015: InSite Vision Announces Settlement of Patent Infringement Lawsuit Against Mylan Pharmaceutical
      • Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US
      • Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops
      • Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops
      • Jun 17, 2013: InSite Vision Announces Joint Patent Infringement Lawsuit With Merck Against Mylan Pharma
      • Mar 26, 2013: InSite Vision Wins Appeal Of Patent Interference Litigation Against University Of California, San Francisco
      • Jan 05, 2012: University Of California, San Francisco Files Appeal Of USPTO Judgment In Favor Of InSite Vision
      • Nov 28, 2011: InSite Vision Wins Patent Interference Litigation Against University Of California, San Francisco
      • Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bacterial Conjunctivitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Bacterial Conjunctivitis - Pipeline by InSite Vision Incorporated, H2 2016
  • Bacterial Conjunctivitis - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2016
  • Bacterial Conjunctivitis - Pipeline by Shire Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Bacterial Conjunctivitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Bacterial Conjunctivitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top